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There is an urgent need to develop the next-generation vectors for gene therapy of muscle
disorders, given the relatively modest advances in clinical trials. These vectors should express
substantially higher levels of the therapeutic transgene, enabling the use of lower and safer
vector doses. In the current study, we identify potent muscle-specific transcriptional cis-
regulatory modules (CRMs), containing clusters of transcription factor binding sites, using a
genome-wide data-mining strategy. These novel muscle-specific CRMs result in a substantial
increase in muscle-specific gene transcription (up to 400-fold) when delivered using adeno-
associated viral vectors in mice. Significantly higher and sustained human micro-dystrophin
and follistatin expression levels are attained than when conventional promoters are used.
This results in robust phenotypic correction in dystrophic mice, without triggering apoptosis
or evoking an immune response. This multidisciplinary approach has potentially broad
implications for augmenting the efficacy and safety of muscle-directed gene therapy.
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Hereditary muscle disorders are characterized by significantmorbidity and mortality due to skeletal muscle and car-diac dysfunction1. Most of these diseases lack effective
treatment, which underscores their unmet medical need. In view
of recent clinical successes2–5, gene therapy offers promising
therapeutic perspectives for many genetic diseases, including
muscle disorders. Most importantly, muscle-directed gene ther-
apy constitutes the basis of the first regulatory approved gene
therapy product6–9.
Most common hereditary muscle disorders are caused by single
gene defects. In particular, Duchenne muscular dystrophy
(DMD) affects 1 in 3500 live newborn males and is caused by
mutations in the dystrophin (DYS) gene10. Patients typically die
at an early age from cardiopulmonary failure after progressive
muscle deterioration11. Long-term expression and therapeutic
effects have been reported after gene therapy using adeno-
associated viral vectors (AAVs) in animal models12–15. Typically,
for gene therapy of DMD, truncated versions of the dystrophin
gene are used (i.e., micro-dystrophin)16,17 that can readily be
accommodated into these AAV vectors. In addition to correcting
muscle diseases per se, the muscle is also an attractive target for
delivery of secreted proteins into the circulation after gene ther-
apy given its secretory capacity18,19.
Despite its promise, it has been particularly challenging to
achieve robust and widespread expression of a given therapeutic
gene in the skeletal muscle18,20–22. For instance, clinical trials for
DMD establish proof of concept that targeting the muscle by gene
therapy is feasible, though the overall therapeutic benefits were
limited20,23. Moreover, muscle-directed oligonucleotide-mediated
exon-skipping strategies did not yet yield the expected outcome in
pivotal trials in patients suffering from DMD24,25, despite
increased dystrophin-expression26,27. Though increasing the
vector doses may result in more efficient gene transfer, this
concomitantly increases the risk of triggering inadvertent
immune reactions28,29. Hence, to overcome these limitations, it is
mandatory to develop more potent gene therapy vectors con-
taining novel promoters that outperform conventional
ones22,30,31 and that consequently allow for high and widespread
muscle-specific expression at lower and safer vector doses.
In the current study, we use genome-wide data-mining to
identify robust transcriptional cis-regulatory modules (CRMs) that
are effective in boosting transcriptional targeting up to 400-fold in
skeletal muscle. This multidisciplinary approach provides new
insights into regulatory motifs and their relative strength in con-
ferring muscle-specific transcriptional control. These novel muscle
CRMs increase expression of micro-dystrophin (MD1)16,17 and
follistatin (FST344), a known myostatin inhibitor32, after gene
therapy with serotype 9 adeno-associated viral vectors (AAV9)33,34.
This results in sustained phenotypic correction in dystrophic mice
without any discernable immune complications.
Results
Computational identification of Sk-CRM. To design robust
muscle-specific gene therapy vectors, we relied on a multistep
computational approach (Fig. 1a) that allowed us to identify
novel evolutionary conserved skeletal muscle-specific cis-reg-
ulatory modules (designated as Sk-CRMs) associated with genes
that are highly expressed in the skeletal muscle (Table 1 and
Supplementary Table 1). Using this computational approach, we
have identified seven different Sk-CRMs based on human
sequences ranging from sizes 344 bp to 519 bp (Table 1, Sup-
plementary Table 1, and Supplementary Fig. 1). These Sk-CRMs
comprised binding sites for seven different transcription factors
(TFs) including E2A, CEBP, LRF, MyoD, SREBP, Tal1, PPAR
(Table 1; Supplementary Fig. 1, and Supplementary Table 2). The
Sk-CRM elements (i.e., Sk-CRM1 to Sk-CRM7) corresponded to
transcription factor binding site (TFBS) clusters in the promoters
or introns of the following muscle-specific genes: ATP2A1 (Sk-
CRM1), TNNI1 (Sk-CRM2, Sk-CRM3), MYLPF (Sk-CRM4);
MYH1 (Sk-CRM5), TPM3 (Sk-CRM6), ANKRD2 (Sk-CRM7)
(Table 1, Supplementary Table 1, and Supplementary Fig. 1).
Several Sk-CRMs contain identical TFBS but each Sk-CRM is
unique with respect to the specific TFBS arrangement. These
distinct Sk-CRMs, therefore, contained a molecular signature that
is characteristic of genes that are highly expressed in the muscle.
The selected Sk-CRMs were relatively conserved in evolution
(Supplementary Fig. 1), suggesting strong selective pressure to
maintain these particular TFBS combinations to enable high
muscle-specific expression. The use of these evolutionary con-
served human Sk-CRMs increased the likelihood that their
potency and specificity is preserved following clinical translation.
In vivo identification of robust muscle-specific Sk-CRM. An
in vivo screening of these Sk-CRMs was subsequently performed
to identify the most robust elements. To achieve this, we cloned
the different Sk-CRMs upstream of a desmin (Des) promoter
(Fig. 1b) that drove the expression of a luciferase (Luc) reporter
gene. The Des promoter was chosen since it is known to confer
relatively high levels of skeletal muscle and heart-specific trans-
gene expression35. The constructs were packaged using AAV
serotype 9 (AAV9) to maximize skeletal muscle and cardiac-
specific gene transfer36–38. The scAAV9-Sk-CRM-Des-Luc vec-
tors containing either Sk-CRM1, Sk-CRM2, Sk-CRM3, Sk-CRM4,
Sk-CRM6, or Sk-CRM7 (Fig. 1c) were then intravenously injected
at a dose of 5 × 109 vg/mouse into neonatal CB17/IcrTac/
Prkdcscid mice. Bioluminescence imaging revealed that 6 out of 6
(100%) (Fig. 2a–c) different Sk-CRMs that were tested in vivo
significantly augmented expression of the luciferase reporter gene
from the Des promoter in distinct skeletal muscle groups but not
in other organs. Most importantly, the Sk-CRM4 element resulted
in an unprecedented and significant 200 to 400-fold increase (t-
test; p < 0.05) in luciferase expression (based on total photon flux)
from the Des promoter in different muscle groups (i.e., gastro-
cnemius, tibialis, quadriceps, biceps, and triceps) (Fig. 2d),
compared to controls without Sk-CRM4. This was consistent with
a significant (t-test; p < 0.01) 60 to 200-fold increase in Luc
mRNA expression in these different muscle groups when the Sk-
CRM4 was used in combination with the Des promoter (Fig. 2e).
Linear regression analysis confirmed a strong correlation between
the luciferase activity and the Luc mRNA levels in the different
muscle groups (correlation coefficient R2= 0.8). Interestingly, the
Sk-CRM4 element also increased luciferase expression in the
diaphragm (i.e., 35-fold) (Fig. 2b–d) but to a lesser extent than in
the other skeletal muscles. This difference likely reflects the lower
intrinsic activity of the Des promoter in the diaphragm (Fig. 2b).
Alternatively, the reduced transduction efficiency with AAV9 in
diaphragm compared to most of the other muscle groups may
also have contributed to the difference in luciferase expression
(Supplementary Fig. 2). Moreover, the selected Sk-CRMs also
significantly increased expression in the heart, reflecting the
tropism of AAV9 and the specificity of the Des promoter (Fig. 2b,
c). In particular, the most robust and significant (t-test; p < 0.05)
increase in cardiac expression was achieved with the Sk-CRM4
(i.e., 36-fold) or Sk-CRM3 elements (i.e., 65-fold) (Fig. 2d).
Despite the relatively broad tissue-tropism of AAV9 (Supple-
mentary Fig. 2), luciferase reporter gene expression was mainly
restricted to skeletal muscle and heart. In particular, liver, kidney,
spleen, and the brain showed no or only limited luciferase
expression with any of the Sk-CRMs (Fig. 2c and Supplementary
Fig. 3). Nevertheless, low-level expression was apparent in the
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lung (Supplementary Fig. 3), albeit substantially less compared to
that in skeletal muscle or heart (Fig. 2c), particularly when the
most robust Sk-CRM4 was employed.
The computational algorithm predicted that Sk-CRM4 con-
tained clusters of TFBS, including CEBP and SRF (Table 1,
Supplementary Tables 1 and 2, and Supplementary Fig. 1). We,
therefore, experimentally confirmed the binding of CEBP and
SRF, on the most potent Sk-CRM4 element by chromatin
immunoprecipitation (ChIP) using gastrocnemius muscle and
heart from mice that were injected with the scAAV9-Sk-CRM4-
Des-Luc vector. In particular, the ChIP assay revealed a
significant 23-fold enrichment in the case of both CEBP and
SRF on the Sk-CRM4 element over the negative control for the
gastrocnemius muscle. Similarly, a specific 12-fold enrichment in
case of CEBP and a 26-fold enrichment for SRF on the Sk-CRM4
element over the negative control were apparent in the heart
(Fig. 2f). Taking into account that the computational motif search
tool estimates the overall probability of a TF binding to a given
promoter region, these ChIP assay results suggest binding of the
respective TFs on a promoter region of the MYLPF gene, that
encompasses the corresponding TFBS elements. Hence, these
ChIP assay results suggest that TF binding on the corresponding
TFBS elements likely contributed to the increased transcriptional
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In vivo validation of Sk-CRM4 fragments. Subsequently, we
assessed whether smaller fragments of the computationally
defined Sk-CRM4 element, were capable of producing an effect
similar to what could be achieved with the full-length Sk-CRM4.
Moreover, since the initial screening was conducted in neonates
(Fig. 2), it was important to also confirm the Sk-CRM4 effect in
adult mice (Fig. 3). These Sk-CRM4 fragments (designated as Sk-
CRM4a, Sk-CRM4b, Sk-CRM4c, Sk-CRM4d, and Sk-CRM4e) were
identified by selecting out smaller fragments within the full-length
Sk-CRM4 containing dense clusters of TFBS (Table 1, Supple-
mentary Fig. 1, and Supplementary Table 1). The scAAV9-Sk-
CRM-Des-Luc vectors (containing either the full-length Sk-CRM4
or its Sk-CRM4a, Sk-CRM4b, Sk-CRM4c, Sk-CRM4d, and and Sk-
CRM4e fragments) were then intravenously injected at a dose of
1010 vg/mouse into adult CB17/IcrTac/Prkdcscid mice. The
scAAV9-Des-Luc vector was used as control. Bioluminescence
imaging revealed that the full-length Sk-CRM4 resulted in a sig-
nificant and robust increase in skeletal muscle-specific expression
(up to 100-fold), compared to the control vector without Sk-
CRM4, in adult mice with no increased expression in other non-
target tissues (Fig. 3 and Supplementary Fig. 4). Though the five
different Sk-CRM fragments significantly augmented expression
in the different skeletal muscle groups and in the heart, the overall
effect was more modest (typically 3 to 9-fold) than what could be
achieved with the full-length Sk-CRM4 element. This indicates
that it is the specific combination of all TFBS clusters within the
full-length Sk-CRM4 element that is required to confer high levels
of transgene expression in the targeted skeletal muscles and heart.
Comparison of promoter strength with conventional pro-
moters. The performance of the Sk-CRM4/Des chimeric pro-
moter was subsequently compared with that of CMV and the
synthetic SPc5-12 promoter, commonly used for muscle gene
therapy. We also combined the most robust Sk-CRM4 element
with the SPc5-12 promoter to assess whether it can further
increase its strength, as in the case of the Des promoter. The
scAAV9-Sk-CRM4-Des-Luc, scAAV9-Des-Luc, scAAV9-Sk-
CRM4-SPc5-12-Luc, scAAV9-SPc5-12-Luc, or scAAV9-CMV-
Luc vectors (Fig. 1b–f) were injected intravenously at a dose of
1010 vg/mouse in adult CB17/IcrTac/Prkdcscid mice. Biolumi-
nescence analysis in vivo (Fig. 4a) or ex vivo (Fig. 4b) on the
isolated muscles revealed that the Sk-CRM4/Des combination was
the most robust Sk-CRM/promoter combination. In particular,
compared to CMV, a significant 25 to 173-fold increase (t-test; p
< 0.01) in transgene expression from the different skeletal muscles
could be attained. Moreover, a significant 12 and 18-fold increase
(t-test; p < 0.05) in luciferase expression could be achieved with
Sk-CRM4/Des in the diaphragm and heart, respectively (Fig. 4c).
Most importantly, Sk-CRM4/Des also outperformed the SPc5-12
and the Sk-CRM4/SPc5-12 promoters (Fig. 4c). These results
suggested that the Sk-CRM4 element did not only increase
expression from the Des promoter but also boosted the perfor-
mance of the SPc5-12 promoter in skeletal muscle and heart,
although to a lesser extent than in the case of the Des promoter.
In particular, when comparing the Sk-CRM4/SPc5-12 chimeric
promoter with the SPc5-12 promoter, a 15- to 30-fold increase in
expression was attained (based on total flux data from different
muscles not including diaphragm). This indicates that the Sk-
CRM4 element has the potential to augment expression from
different muscle-specific promoters, the extent of which varies
depending on the intrinsic strength of those promoters.
Therapeutic validation in a dystrophic mouse model. We
subsequently validated the performance of the Sk-CRM4/Des
chimeric promoter in a preclinical gene therapy setting. We,
therefore, generated AAV9 vectors expressing either a truncated
codon-usage optimized human micro-dystrophin (MD1Δ)
(Fig. 1g) or a human follistatin cDNA (FST344) (Fig. 1k). Injec-
tion of ssAAV9-Sk-CRM4-Des-MD1Δ by itself or in combination
with ssAAV9-Sk-CRM4-Des-FST in SCID/mdx mice resulted in
widespread MD1 expression in heart and skeletal muscles
(Fig. 5a, b), consistent with a significant percentage (Fig. 5c) of
dystrophin-positive fibers (DYS+) in both heart and skeletal
muscle compared to untreated control SCID/mdx mice. Similarly,
injection of ssAAV9-Sk-CRM4-Des-FST by itself or in combi-
nation with AAV9-Sk-CRM4-Des-MD1Δ resulted in significantly
higher FST protein levels (Fig. 5d) expression in skeletal muscle
Table 1 Sequence and details of the Sk-CRMs
Name Genes Length (bp) TFBS
SK-CRM1 ATP2A1 495 E2A, CEBP, LRF, MyoD
SK-CRM2 TNNI1 344 E2A, CEBP, LRF, MyoD, SREBP
SK-CRM3 TNNI1 430 E2A, CEBP, LRF, MyoD, SREBP,
Tal1.
SK-CRM4 MYLPF 435 E2A, CEBP,LRF, MyoD, SREBP
SK-CRM4a 171 CEBP, E2A, LRF
SK-CRM4b 51 CEBP, E2A, LRF
SK-CRM4c 60 E2A, LRF, MyoD
SK-CRM4d 41 LRF, MyoD
SK-CRM4e 120 CEBP, E2A, LRF
SK-CRM5 MYH1 474 PPAR, CEBP, LRF, SREBP
SK-CRM6 TPM3 519 E2A, CEBP, LRF, MyoD, SREBP
SK-CRM7 ANKRD2 372 E2A, CEBP, MyoD
Fig. 1 Flow diagram for the identification of muscle-specific cis-regulatory modules (CRMs) and AAV constructs for in vivo validation. a A computational
approach was used to identify the Sk-CRMs involving the following five steps: (1) identification of tissue-specific genes that are highly and lowly expressed
based on statistical analysis of micro-array expression data of normal human tissues; (2) extraction of the corresponding promoter sequences from
publicly available databases; (3) identification of the CRMs and the transcription factor binding sites (TFBS) they contain using a differential distance matrix
(DDM)-multidimensional scaling (MDS) approach; (4) search for evolutionary conserved clusters of TFBS (i.e., CRM) of the highly expressed genes (5)
ENCODE filtering. The identified Sk-CRMs were subsequently included in an expression construct and validated in vivo by testing whether they increased
promoter activity. b–m Schematic representation of all the different AAV vectors encoding either the reporter or therapeutic genes. The different
expression cassettes were packaged in an adeno-associated virus vector flanked by inverted terminal repeats (ITR) from AAV serotype 2 (AAV2) and
produced with an AAV serotype 9 (AAV9) capsid. The expression cassette further comprises the Minute Virus of Mouse (MVM) intron and a Simian virus
40 (SV40) polyadenylation signal (pA). b The scAAV-Des-Luc vector is a self-complementary AAV vector (scAAV) containing the luciferase (Luc) gene
driven from the desmin (Des) promoter without the CRM used as a control c the scAAV-Sk-CRM-Des-Luc vectors contain the Sk-CRM 1-7 cloned upstream
the Des promoter. d The scAAV-CMV-Luc vector uses the CMV promoter to drive the Luc gene. e The scAAV-SPc5-12-Luc vector has the same vector
configuration as in b where the Des promoter was replaced by the SPc5-12 promoter. f The scAAV-Sk-CRM4-SPc5-12-Luc vector contains the Sk-CRM4
element cloned upstream of the SPc5-12 promoter driving the expression of the Luc gene. The single-stranded AAV (ssAAV) vectors were used to deliver
therapeutic genes g–j micro-dystrophin (MD1Δ or MD1) and k–m the follistatin (FST344), respectively, with SkCRM4/Des chimeric promoter or CMV and
Des conventional promoters. The cognate FST protein is encoded by a FST-2A-Luc polycistronic transcript
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compared to untreated control SCID/mdx mice. These results
were consistent with significantly elevated levels of MD1Δ or FST
transcripts in transduced skeletal muscle and heart of SCID/mdx
mice (Fig. 5e).
SCID/mdx mice treated with the ssAAV9-Sk-CRM4-Des-
MD1Δ and ssAAV9-Sk-CRM4-Des-FST alone or in combination,
outperformed the untreated control mice in treadmill test
16 weeks post vector injection (Fig. 6a). In particular, the
performance of dystrophic mice treated with the ssAAV9-Sk-
CRM4-Des-MD1Δ or ssAAV9-Sk-CRM4-Des-FST vector
increased with 300% (t-test; p < 0.001) and 250%, respectively,
compared to untreated dystrophic mice. Most importantly, the
performance of dystrophic mice that received combination gene
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and ssAAV9-Sk-CRM4-Des-FST showed a robust 356% increase,
compared to untreated dystrophic mice (Fig. 6a). This was
consistent with a significant 1.8-fold increase (t-test; p < 0.05) in
absolute tetanic contraction force ex vivo on isolated extensor
digitorum longus (EDL) muscle from SCID/mdx mice that
received the combination gene therapy, approximating the EDL
absolute contraction force in wild-type C57BL/6 mice (191+ 58
mN in MD1Δ/FST-treated SCID/mdx; 105+ 13 mN in untreated
SCID/mdx; 232+ 42 mN wild-type C57BL/6).
We subsequently corroborated the functional correction after
gene therapy by histopathological examination of the skeletal
muscle. The central localization of the nucleus in the muscle
fibers is one of the hallmarks of muscular dystrophy, as opposed
to peripheral nuclear localization in normal, non-dystrophic
muscle fibers. Hematoxylin and eosin staining of the tibialis
anterior muscle revealed a significant reduction (t-test; p <
0.0001) in centrally nucleated muscle fibers after systemic gene
therapy with ssAAV9-Sk-CRM4-Des-MD1Δ and/or ssAAV9-Sk-
CRM4-Des-FST compared to non-treated SCID/mdx mice
(Fig. 6b, c). Moreover, the combination therapy based on co-
delivery of both ssAAV9-Sk-CRM4-Des-MD1Δ and ssAAV9-Sk-
CRM4-Des-FST resulted in an even more pronounced and
significant effect (t-test; p < 0.001) on the nuclear re-localization
towards the muscle fiber periphery than by either of the single
vector treatments (Fig. 6b, c). Furthermore, the fiber cross-
sectional area also increased after gene therapy with the Sk-
CRM4-based vectors. In particular, treatment of SCID/mdx mice
with the ssAAV9-Sk-CRM4-Des-MD1Δ vector significantly
increased the cross-sectional area 130% (t-test; p < 0.001) (Fig. 6d)
compared to untreated SCID/mdx mice. The effect was even
250% greater following ssAAV9-Sk-CRM4-Des-FST treatment (t-
test; p < 0.0001), exceeding the fiber cross-sectional area typically
observed in wild-type mice (Fig. 6d). The maximum effect could
be attained upon co-delivery of ssAAV9-Sk-CRM4-Des-MD1Δ
and/or ssAAV9-Sk-CRM4-Des-FST resulting in a 285% increase
in fiber cross-sectional area (t-test; p < 0.001). In conclusion, the
impact of gene therapy on the improvement of the histopatho-
logical features characteristic of a dystrophic phenotype was
consistent with its effect on overall physical performance and
muscle function.
Comparative analysis of therapeutic efficiency. The perfor-
mance of the Sk-CRM4/Des chimeric promoter was subsequently
compared with other conventional promoters, such as Des and
CMV (Fig. 1i, j, l, m), which are generally used for therapeutic
gene expression in skeletal muscles and being used in clinical
trials for muscle-directed gene therapy. Comparative functional
analysis 16 weeks post-injection (Fig. 7a) revealed that robust and
sustained phenotypic correction could be achieved in SCID/mdx
mice co-injected with the ssAAV9-SkCRM4-Des-MD1 (Fig. 1i)
and ssAAV9-SkCRM4-Des-FST (Fig. 1l) vectors resulting in a
normalization of the running distance covered, comparable to
that of wild-type mice (Student’s two-tailed t-test; p-value=
0.6245, non-significant). This represent a robust ≈800%
improvement in distance traveled compared to the untreated
dystrophic SCID/mdx mice (t-test; p < 0.01). Hence, this is con-
sistent with a bona fide cure of muscular dystrophy in this pre-
clinical model when the next-generation AAV9 vectors that
expressed the MD1 and FST genes from the de novo designed
SkCRM4-Des promoter. Most importantly, the therapeutic effect
was significantly increased (t-test; p < 0.05) when the SkCRM4/
Des promoter was used compared to when the therapeutic MD1
and FST genes were driven from either CMV or Des promoters
(Fig. 7a).
Next, the MD1 and FST mRNA and protein expression levels
were determined using qRT-PCR (Fig. 7b) and ELISA (Fig. 7c) or
western blotting (Fig. 7d), respectively. The new muscle-specific
Sk-CRM4/Des chimeric promoter led to a robust increase in MD1
and FST (Figs. 7b and 8b) mRNA expression levels compared to
when CMV or Des promoters were used, as control. This
translated in a significant (t-test; p < 0.01) increase in MD1 in
heart, diaphragm and skeletal muscle (gastrocnemius) (Fig. 7d)
and FST (Fig. 7c) protein expression when the Sk-CRM4/Des
chimeric promoter was used compared to the CMV or Des
promoters. The western blot analysis confirmed that MD1 had
the expected molecular weight (136 kD) (Fig. 7d and Supple-
mentary Fig. 6). Hence, the increased therapeutic efficacy with the
next-generation AAV vectors expressing the MD1 and FST
therapeutic genes from the Sk-CRM4/Des chimeric promoter was
consistent with the increase in MD1 and FST expression. These
results suggested that the use of the Sk-CRM4/Des chimeric
promoter provided an effective and sustained therapeutic effect
that is significantly more robust compared to conventional
promoters typically used for DMD gene therapy.
In addition to the SCID/mdx model, the efficacy of the Sk-
CRM4/Des constructs for DMD treatment was also validated in
an immunocompetent dystrophic mouse model (mdx) and
compared with conventional promoters (Fig. 8a–c). Co-
injection of mdx mice with the ssAAV9-SkCRM4-Des-MD1
and ssAAV9-SkCRM4-Des-FST vectors resulted in a significant
Fig. 2 Screening and validation of novel hyperactive Sk-CRMs. CB17/IcrTac/Prkdcscid mice were intravenously injected with 5 × 109 vg per neonatal mouse.
a In vivo whole-body bioluminescence imaging of mice injected intravenously with scAAV9-Des-Luc2 (control, no Sk-CRM), scAAV9-Sk-CRM1-Des-Luc
(Sk-CRM1), scAAV9-Sk-CRM2-Des-Luc (Sk-CRM2), scAAV9-Sk-CRM3-Des-Luc (Sk-CRM3), scAAV9-Sk-CRM4-Des-Luc (Sk-CRM4), scAAV9-Sk-CRM6-
Des-Luc (Sk-CRM6), or scAAV9-Sk-CRM7-Des-Luc (Sk-CRM7) vector were shown based on a color scale from 2.0e+ 04 (blue) ph/s/cm2/sr to 1.59e+
06 (red) ph/s/cm2/sr at week 5 and 6 post vector injection. Photon emission was measured dynamically during 7min in a supine position. b Ex vivo
bioluminescence imaging of individual organs harvested at week 7 post vector injection was represented on a color scale with luciferase intensities ranging
from 3.23e+ 04 (blue) ph/s/cm2/sr to 2.05e+ 05 (red) ph/s/cm2/sr. The bioluminescence signal was quantified for 5 min. c A hand-drawn region of
interest (ROI) was used for every individual tissue. Luciferase expression from the individual muscles was measured as total flux, expressed in photons/
sec/cm2/sr. d Fold-difference of the total flux measured from the different muscles upon ex vivo bioluminescence imaging with respect to the control
(construct without Sk-CRM). e Fold-difference in Luc mRNA expression levels from the different muscles, measured by qRT-PCR from total RNA extracted
from biopsies of the indicated tissues. Results were presented as mean ± standard error of the mean, fold-difference in Luc mRNA expression with respect
to the control (construct without Sk-CRM). f Chromatin immune-precipitation (ChIP) assay for the heart and gastrocnemius muscle of mice injected with
scAAV9-Sk-CRM4-Des-Luc (5 × 109 vg/mouse). Antibodies specific for CEBP and SRF and PCR primers specific for the corresponding TFBS were used.
PCR primers were designed to amplify a region corresponding to Sk-CRM4 that binds CEBP and SRF and an untranscribed region on chromosome 17 was
used as a negative control. Binding events for 103 cells were determined for each of the corresponding primer pairs. The black bars represent the negative
control and the white bars correspond to Sk-CRM4; heart (left panel), gastrocnemius (right panel). Significant differences compared to the negative control
were indicated (t-test, *p≤ 0.05, mean+ s.e.m.; n= 2–4)
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increase (t-test; p < 0.05) in therapeutic efficacy based on a
treadmill assay, at all vector doses tested, consistent with a
significant increase in MD1 or FST mRNA (Fig. 8b) or protein
expression levels (Fig. 8c). Notably, even at a fivefold lower vector
dose (i.e., 1011 vg) the SkCRM4-Des-containing vectors out-
performed the vectors that expressed the MD1 or FST therapeutic
transgenes from either the CMV or Des promoters resulting in
higher transgene expression levels resulting in a significant
increase in overall therapeutic efficacy. Collectively, these results
indicate that this new SkCRM4 transcriptional element lowers
vector dose requirement.
Lastly, we examined the extent of the apoptosis using a TUNEL
assay. Analysis of skeletal muscle (tibialis anterior) from mdx mice
injected with the different AAV9 vectors expressing MD1 or FST
from the SkCRM4-Des, Des or CMV promoters (at 5 × 1011 vg/
mouse for each vector) revealed that there was no significant
increase in apoptotic cells compared to untreated control mdx or
wild-type control mice (Supplementary Fig. 7a). Moreover,
immunohistochemistry for staining CD4 and CD8-positive T cells
in the muscles revealed no significant increase in T-cell infiltration
in skeletal muscle from mdx mice injected with the various AAV9
vectors expressing MD1 or FST from the SkCRM4-Des, Des or
CMV promoters (Supplementary Fig. 7b). Hence, this indicates that
over-expression of MD1 or FST in the skeletal muscle with the
next-generation ssAAV9-SkCRM4-Des-MD1 and ssAAV9-
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Fig. 3 Screening and validation of Sk-CRM4 fragments. a In vivo bioluminescence imaging at week 2 and week 4 post vector injection and quantification of
luciferase expression from the different individual organs of adult CB17/IcrTac/Prkdcscid mice injected intravenously with scAAV9-Des-Luc2 (control, no
Sk-CRM), scAAV9-Sk-CRM4a-Des-Luc, scAAV9-Sk-CRM4b-Des-Luc, scAAV9-Sk-CRMc-Des-Luc, scAAV9-Sk-CRM4d-Des-Luc, and scAAV9-Sk-CRM4e-
Des-Luc vectors at a dose of 1 × 1010 vg per mouse. The corresponding color scale from 6.70e+ 03 (blue) ph/s/cm2/sr to 2.70e+ 05 (red) ph/s/cm2/sr
was shown. Photon emission was measured dynamically during 7min in a supine position. b Ex vivo bioluminescence imaging of individual organs such as
the heart and the different muscle groups harvested at 6 weeks post vector injection was represented on a color scale with luciferase intensities ranging
from 5.92e+ 03 (blue) ph/s/cm2/sr to 5.08e+ 04 (red) ph/s/cm2/sr. The bioluminescence signal was quantified for 5 min. c Luciferase expression from
the individual tissues was measured as total flux, expressed in photons/sec/cm2/sr. The fold-difference of the total flux was indicated for each Sk-CRM4
fragments relative to that of the control group containing the Des promoter without any Sk-CRM. The total flux data were displayed as mean+ s.e.m. (n=
3)
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Discussion
In this study, we have identified novel and potent muscle-specific
CRMs using an improved genome-wide computational algorithm.
In particular, the most potent Sk-CRM4 element resulted in a
substantial improvement in transcription (up to 400-fold) when
combined with the muscle-specific desmin promoter, one of the
most commonly used muscle-specific promoters35,39,40. In addi-
tion, a 36-fold increase in cardiac expression could be attained.
To our knowledge, this type of computational vector design
represents the first of its kind to improve the performance of a
gene therapy vector for muscle-directed gene therapy, yielding an
unprecedented increase in muscle-specific gene expression.
Indeed, our previously identified cardiac-specific CRM failed to
increase muscle-specific expression from the synthetic SPc5-12
promoter, in contrast to the present study41. Moreover, the
muscle-specific Sk-CRM4/Des chimeric promoter outperformed
the commonly used CMV promoter, up to 100- to 200-fold in
most muscle groups and thus provides an attractive alter-
native34,42. In particular, the CMV promoter was employed to
drive expression of the lipoprotein lipase (LPLS447X) gene that
constitutes the basis of the first approved AAV-based gene
therapy product6,7. Our current results underscore the potential
of these computationally designed CRMs to improve the efficacy
of skeletal muscle-directed and cardiac gene therapy of DMD,
with broad implications for other muscle disorders. In particular,
the combination of the de novo designed Sk-CRM/Des muscle-
specific promoter with the use of the AAV9 muscle-tropic ser-
otype resulted in widespread expression of reporter or therapeutic
genes (i.e. micro-dystrophin, follistatin) in heart and skeletal
muscle following systemic gene delivery in neonatal or adult
mice. This was consistent with robust phenotypic correction of
the dystrophic phenotype in DMD mice resulting in long-term
improvement of the physical performance and restoration of
several characteristic dystrophic pathophysiological features,
particularly increased muscle fiber size and re-localization of the
fiber nuclei from the nuclei towards the periphery. Previous
efforts to augment muscle-directed gene expression by promoter
optimization and/or AAV capsid engineering typically resulted in
more modest and incremental increases in gene expression.
Moreover, though muscle-specific promoters are often preferred
by virtue of their tissue-specificity, they typically yield much
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Fig. 4 Comparison of Sk-CRM/promoter combinations with conventional promoters. a In vivo bioluminescence imaging at week 2 and week 4 post vector
injection in adult CB17/IcrTac/Prkdcscid mice intravenously injected with the different scAAV9 luciferase vectors containing the different promoters (CMV,
Des, Sk-CRM4/Des, SPc5-12, Sk-CRM4/SPc 5-12) at a dose of 1 × 1010 vg per mouse. A color scale from 6.7e+ 03 (blue) ph/s/cm2/sr to 2.7e+ 05 (red)
ph/s/cm2/sr was shown. Photon emission was measured dynamically during 7min. b Ex vivo bioluminescence imaging of individual tissues harvested at
6-week post vector injection was represented on a color scale with luciferase intensities ranging from 3.80e+ 03 (blue) ph/s/cm2/sr to 2.02e+ 04 (red)
ph/s/cm2/sr. The bioluminescence signal was quantified for 5 min. c Luciferase expression from the individual tissues was measured as total flux,
expressed in ph/s/cm2/sr. The fold-difference of the total flux of the SkCRM4/Des chimeric promoter was indicated relative to the CMV promoter (without
any Sk-CRM). The luciferase signal were showed as mean+ s.e.m. (n= 3)
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like CMV35 that are sometimes prone to transcriptional silencing
in vivo43. The incorporation of the Sk-CRM4 element upstream of
the desmin (Des) promoter overcomes this limitation by boosting
muscle-specific gene expression levels by several orders of mag-
nitude, based on reporter genes (i.e., luciferase). The generation of
synthetic muscle-specific promoters (i.e., SPc5-12) by molecular
assembly and selection of muscle-specific TFBS combinations in
muscle cell lines in vitro has been proposed as an alternative
strategy to boost muscle-specific gene expression31,44. However,
this in vitro selection approach resulted in a relatively modest and
incremental six-fold increase in muscle-specific expression rela-
tive to the CMV promoter, which is in contrast to the robust 100-
fold increased expression attained with the computationally
designed Sk-CRM4/Des chimeric promoter relative to CMV. In
particular, head-to-head comparative analysis revealed that the
Sk-CRM4/Des promoter is 15- to 30-fold more potent than the
synthetic SPc5-12 promoter (Fig. 4a–d). The current computa-
tional approach distinguishes itself from this synthetic molecular
assembly and in vitro selection method by allowing comprehen-
sive and genome-wide identification of evolutionary conserved
TFBS clusters that are associated with highly expressed, muscle-
specific genes in human muscle in vivo. Consequently, this
translated into a more robust increase in expression after gene
therapy in vivo, compared to what could be achieved using
synthetic promoters obtained by in vitro assembly and
selection31,44.
The different muscle-specific human CRMs were retrieved
from their natural in vivo context following a genome-wide
screening and contained a molecular signature composed of TFBS
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Fig. 5 Human MD1 and human FST expression analysis in immunodeficient dystrophic SCID/mdx mice. The ssAAV9-Sk-CRM4-Des-MD1Δ and ssAAV9-
Sk-CRM4-Des-FST vectors were injected either alone (indicated as MD1Δ, FST) or in combination (indicated as MD1Δ+ FST) in SCID/mdx mice at a dose
of 2 × 1010 vg/mouse. a, b Immunofluorescence staining for laminin (LAM, in green), human dystrophin (DYS, in red) and DAPI nuclear staining (in blue)
was performed on sections from heart (a) and skeletal muscles (b) of treated and untreated control SCID/mdx mice. The scale bars indicate 100 μm.
c Quantification of the DYS+ fibers detected out of the total number of LAM+ fibers in the heart and skeletal muscle tissue sections from treated and
untreated control SCID/mdx mice. d Quantification of human FST protein (in pg/50mg of skeletal muscle tissue) as determined by ELISA. e HumanMD1Δ
and FST mRNA quantification in the heart and the skeletal muscles (i.e., gastrocnemius, quadriceps) of treated and untreated control SCID/mdx mice,
expressed relative to the murine housekeeping gene Gapdh by qRT-PCR. Mice were injected at 4 weeks and euthanized 22 weeks later. The data were
represented as mean+ s.e.m. (n= 2–4)
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Fig. 6 Phenotypic correction of muscular dystrophy in SCID/mdx mice. a SCID/mdx mice injected with ssAAV9-Sk-CRM4-Des-MD1Δ only, ssAAV9-Sk-
CRM4-Des-FST only, and ssAAV9-Sk-CRM4-Des-MD1Δ with ssAAV9-Sk-CRM4-Des-FST combination therapy (2 × 1010 vg/mouse of each vector) were
subjected to a treadmill assay. Physical performance of the 20-week-old SCID/mdx mice treated with the different therapeutic vectors compared to the
untreated age-matched control SCID/mdx mice was determined by measuring the distance covered. Results were presented as mean ± standard error of
the mean, (% increase in distance covered relative to untreated SCID/mdx was indicated. b–d Improvement of pathophysiological properties in SCID/mdx
mice injected with ssAAV9-Sk-CRM4-Des-MD1Δ, ssAAV9-Sk-CRM4-Des-FST, ssAAV9-Sk-CRM4-Des-MD1Δ, and ssAAV9-Sk-CRM4-Des-FST
combination therapy. b Hematoxylin and eosin staining of 5 μm thick transverse sections of the tibialis anterior muscle from mice treated with the different
therapeutic vectors were compared with those of age-matched control C57BL/6 and SCID/mdx mice treated with PBS. The scale bars indicate 50 μm.
c Graphical representation of the % of central nucleation in muscle fibers from treated sections versus the age-matched non-treated sections. Results were
presented as mean ± standard error of the mean, ***p < 0.001 and ****p < 0.0001 using Student’s t-test (n= 4–9). d Muscle fiber cross-sectional area
(expressed in pixels) of each of the different groups of SCID/mdx mice treated with the different therapeutic vectors (at a dose of 2 × 1010 vg/mouse).
Untreated SCID/mdx and C57BL/6 mice were used as controls. Results were presented as mean ± standard error of the mean, *p < 0.05; ***p < 0.001, and
****p < 0.0001 using Student’s t-test (n= 4–5)
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Tal1, PPAR) that are characteristic of highly expressed genes in
the muscle. In particular, the Sk-CRM4 and Sk-CRM1 elements
are among the most potent muscle-specific CRMs that have
several TFBS in common (i.e., E2A, LRF, CEBP, andMyoD). They
were derived from quintessential human muscle-specific genes
MYLPF and APTP2A1 that encode for the myosin light chain and
the sarcoplasmic/endoplasmic CA2+ ATPase (SERCA), respec-
tively. Since MYLPF and APTP2A1 are typically highly expressed
in fast twitch muscle, this may possibly account for the higher
activity of Sk-CRM4 and Sk-CRM1 in the fast twitch skeletal
muscles, whereas their activity was lower in low twitch muscle,
like diaphragm. Nevertheless, the reduced gene transfer in the
diaphragm compared to that in other muscles may also have
contributed to the reduced gene expression (Supplementary
Fig. 2). The increased protein expression from the CRM-driven
constructs correlated strongly with increased transcriptional
activity. This was consistent with the increased binding of CEBP
and SRF on the MYLPF promoter regions encompassing the
respective TFBS that were mapped within the Sk-CRM4 element.
The main advantage of this novel computational approach
used to identify the tissue-specific CRMs is that it takes into
account the actual context-dependent TFBS interactions from a
broad genome-wide perspective in vivo, instead of just relying on
the over-representation of a single TFBS in a given tissue-specific
CRM. Consequently, this computational analysis is more com-
prehensive and allows for the identification of TFBS elements that
tend to cluster together in CRMs of genes that are highly
expressed in the skeletal muscle and the heart (Table 1), based on
a differential distance matrix-multidimensional scaling (DDM-
MDS)45. DDM-MDS is a count-based method that evaluates the
statistical significance of the observed versus expected numbers of
TFBSs in the sets of promoters. The main difference with
methods that only consider over-representation is that a data
structure is used that allows simultaneous evaluation of the
degree of association between TFBSs for different TFs. The
DDM-MDS method45 produces more relevant and/or repro-
ducible results compared to other methods such as LogicMotif46,
POCO47, and CRÈME48. Another advantage of this DDM-MDS
approach is does not need to rely on a comprehensive database
containing all muscle-specific genes, but merely a gene set cor-
responding to the most highly expressed genes, The analysis is
most robust if we restrict ourselves to a selection of these most
highly expressed muscle-specific genes rather than a compre-
hensive list of all muscle-specific genes (see Supplementary
Method). In the current study, the analysis was based on 29
promoters which falls in a similar range as our recent studies, that
are based on 43 or 59 to identify cardiac-specific or liver-specific
CRMs, respectively41,49,50.
Our computational approach takes into account cross-species
evolutionary conservation of the selected Sk-CRM elements
(Supplementary Fig. 1). Cross-species comparison significantly
improves genome-wide prediction of CRMs51,52. This justifies
prioritizing CRMs based on evolutionary conservation. Conse-
quently, such evolutionary conserved CRMs are likely to exhibit
the same properties across distinct species with respect to tissue-
specificity and expression levels. This is important for gene
therapy as tissue-specificity and expression levels based on a given
CRM may then likely be conserved in preclinical models and
human subjects. This potentially improves the prospects for
clinical translation. Indeed, if a sequence is conserved and is
associated with highly expressed genes in a given species, it will
likely be associated with high expression in other species as well.
Nevertheless, evolutionary conservation in as of itself does not
necessarily imply that the CRMs are evolutionarily optimized and
selected for to maximize expression.
Open chromatin structures, as defined in the ENCODE data-
base53 were considered in the current computational analysis,
which distinguishes the current approach from our previous
strategies used to maximize tissue-specific gene expression after
gene therapy41,49,50. We, therefore, considered chromatin con-
textual features better describing features like DNA accessibility,
nucleosome occupancy, or the presence of specific histone post-
translational modifications associated with transcription regula-
tion. In practice, candidate Sk-CRMs were mapped against the
human hg19 genome using the blat tool at the UCSC genome
browser (https://genome.ucsc.edu). Next, the mapped regions
were visualized along the ENCODE Regulation supertrack con-
taining information relevant to regulation of transcription from
the ENCODE project. The layered H3K4Me1 and layered
H3K27Ac marks are epigenetic signatures often found near reg-
ulatory elements, while the DNase I hypersensitivity tracks
indicate where chromatin is hypersensitive to cutting by DNase I
and are associated with both regulatory regions and promoters.
The open chromatin structure is used as a filter in the selection of
candidate CRMs because this indicates that, at least in some
conditions, a particular genomic region is accessible to TFs. In
contrast, some chromatin features may reduce the accessibility of
the DNA and therefore impede expression, despite the presence
of other favorable features. Moreover, chromatin effects are
known to influence expression from AAV vectors as AAV adopts
a chromatin-like configuration54–56.
Enhancers typically activate gene expression when they are
located at far greater distances from the transcriptional start site
(TSS). However, such distal enhancers may increase the risk of
insertional oncogenesis following vector integration in the target
cell genome57,58. Hence, we strategically focused on selecting
CRMs that are located within the proximal promoter (i.e., < 2.5 kb
from TSS) to diminish the risk of insertional oncogenesis when
used in the context of gene therapy. We have previously
demonstrated that CRMs that have been identified with the
DDM-MDS method and that are located within a 2 kb region
from the TSS (i.e., HS-CRM849,50), do not significantly increase
the risk of insertional oncogenesis, in normal or highly sensitive
tumor-prone mouse models, even when vectors are employed
that integrate at high efficiencies in the target cell genome59.
The overall efficiency of this next-generation AAV-based
muscle-directed gene therapy compares favorably to the state of
the art vectors as higher expression levels could be attained
leading to an increased therapeutic efficacy. Previous studies were
based on intramuscular AAV injections, which did not allow
body-wide expression of the therapeutic micro-dystrophin and
consequently resulted in a more modest correction of the dys-
trophic phenotype30,60. Moreover, substantial correction of the
dystrophic phenotype could be achieved in a physical endurance
test (i.e., treadmill assay) either using a single or a combination of
therapeutic genes (i.e., MD1 or FST).
The overall impact of the Sk-CRM4 element on gene expression
may vary depending on the transgene. Indeed, though the Sk-CRM4
element led to a significant increase in both MD1 and FST tran-
scription, the highest relative- increase in mRNA levels was
apparent when luciferase was used. Moreover, the significant
increase in MD1 and FST protein levels was not directly propor-
tionate to the increased transcription. This suggests that additional,
potentially unknown, post-transcriptional or translational bottle-
necks may influence gene therapy efficacy. Though over-expressing
a potential therapeutic gene might lead to imbalanced protein
synthesis followed by muscle fiber death, lack of apoptosis or T-cell
infiltration further supports the safety of the current vector designs
and allowed for the use of lower vector doses to attain an increased
therapeutic effect compared to more conventional vector designs.
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Other studies that were based on systemic intravenous injec-
tion of AAV vectors encoding therapeutic genes typically
required higher vector doses than the therapeutic doses used in
the present study16,17 and/or requiring the use of vascular
endothelial growth factor (VEGF164), raising additional safety
concerns. Lower vector doses may minimize the risk of potential
AAV-specific T-cell immune response in human trials and may
ease manufacturing constraints. The first gene therapy trials for
DMD had been initiated based on intramuscular delivery of an
AAV2.5 variant encoding mini-dystrophin20. Overall,
dystrophin-expression in patient’s biopsies was either absent or



































































































































































































































































Fig. 7 Comparison of Sk-CRM4/Des chimeric promoter with conventional promoters in SCID/mdx. The ssAAV9 vectors encoding MD1 and FST under the
control of the Sk-CRM4/Des chimeric promoter, Des, or CMV conventional promoters were co-injected into SCID/mdx mice at a dose of 1 × 1011 vg/mouse
for each vector. a Physical performance of the 16 weeks post-injected SCID/mdx mice treated with the different therapeutic vectors compared to the
untreated age-matched control SCID/mdx and wild-type C57BL/10ScSnJ mice were determined by measuring the distance covered. Results were
presented as mean ± standard error of the mean (n= 3–6). The percentages on the top indicate the distance related to untreated SCID/mdx mice.
b Human MD1 and FST mRNA quantification in skeletal muscles (i.e., gastrocnemius and quadriceps) of treated SCID/mdx mice, expressed relative to the
housekeeping gene Gapdh by qRT-PCR. The Gapdh protein levels were used as loading control for normalization. c Quantification of human FST protein (in
pg/50mg of skeletal muscle tissues) as determined by ELISA. d Western blot analysis of MD1 protein expression in heart, diaphragm and skeletal muscle
(gastrocnemius) of treated and control SCID/mdx. The protein expression levels of MD1 were detected using a dystrophin-specific (DYS3) antibody.
Statistical analysis using t-test *p < 0.05; **p < 0.01; ***p < 0.001, ****p < 0.0001; mean+ s.e.m. (n= 3–6)
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approaches failed to demonstrate any long-term effects25,61. The
next-generation vector design described in the present study may
potentially overcome some of these bottlenecks and pave the way
towards clinical applications to treat DMD and other muscle
disorders.
Methods
Identification of Sk-CRM. We designed a computational approach (Fig. 1a)
(Supplementary Methods) to specifically identify robust skeletal muscle CRMs (Sk-
CRMs). This approach consisted of five steps: (1) muscle-specific genes were
identified that are highly and lowly expressed based on statistical analysis of micro-
array expression data of normal human tissues;62,63 (2) publicly available databases
were used to extract the corresponding promoter sequences (NCBI36/hg18 genome
assembly) (3) a differential distance matrix (DDM)-multidimensional scaling
(MDS) approach45 was used to identify the regulatory modules and the TFBS they
contain (4) the genomic context of the highly expressed genes was then screened
for evolutionary conserved clusters of TFBS (i.e., CRMs). A detailed description of
these four successive steps for identification of tissue-specific CRM was described,
that led to the identification of robust liver-specific or cardiac-specific CRMs41,49,50.
However, in the present study we further refined this computational analysis by
adding an extra step that also takes into consideration biochemical features asso-
ciated with transcription regulation and/or open chromatin structures, as defined
in the ENCODE database (Supplementary Methods)53. Six different Sk-CRMs were
selected based on this computational analysis (Table 1).
Generation of Sk-CRMs AAV constructs. The CRMs were synthesized by con-
ventional oligonucleotide synthesis (Geneart, Thermo Fisher Scientific, Carlsbad,
California, USA) and were flanked with MluI and Acc65I restriction sites at the 5ʹ
and 3ʹ’ ends, respectively. After synthesis, the Sk-CRMs were cloned upstream of
the desmin (Des) promoter (983 bp) (Invivogen, France) in a self-complementary
adeno-associated viral (scAAV) vector64 (kindly provided by Dr. Srivastava, Uni-
versity of Florida College of Medicine, USA). This vector encoded for the firefly
luciferase (Luc) reporter gene and also contained the Minute Virus of Mouse
(MVM) intron and a simian virus 40 (SV40) polyadenylation site (pA). The cor-
responding scAAV constructs that contained these Sk-CRM elements were
designated as pscAAV-Sk-CRM-Des-Luc (Fig. 1c). An AAV vector without the Sk-
CRM was used as control (designated as pscAAV-Des-Luc) (Fig. 1b). For com-
parison, the most robust Sk-CRM4 (Supplementary Table 1) was cloned in com-
bination with a synthetic promoter (SPc5-12)31, known for expression in the
skeletal muscle and heart, within the scAAV vector backbone to drive the luciferase
reporter (designated as pscAAV-Sk-CRM4-SPc5-12-Luc) (Fig. 1f). The corre-
sponding control AAV vector without the Sk-CRM4 was also generated (designated
as pscAAV-SPc5-12-Luc) (Fig. 1e). Additionally, the cytomegalovirus promoter
(CMV)17, often used as gold standard to achieve high expression in the muscle, was
cloned into the scAAV backbone encoding luciferase for comparison (designated as
pAAV-CMV-Luc-SV40pA) (Fig. 1d). Next, five different sub-fragments of Sk-
CRM4 were synthesized by conventional oligonucleotide synthesis and were cloned
upstream of the desmin promoter in the same scAAV backbone encoding luci-
ferase. The constructs generated were designated as pssAAV-Sk-CRM(a-e)-Des-Luc.
In order to validate these CRMs for gene therapy of DMD, we cloned human
micro-dystrophin 1 (MD1)30 or an alternative truncated version (MD1Δ) con-
taining additional deletions of the spectrin-like repeats (Supplementary Fig. 5) and
human follistatin (FST344)34 cDNA into a single-stranded AAV (ssAAV) vector
driven from the Sk-CRM4/Des chimeric promoter. The MD1 cDNA was flanked by
MluI and XhoI restriction sites at the 5ʹ and 3ʹ ends while the FST cDNA was
flanked by MluI and SalI restriction sites at the 5ʹ and 3ʹ, respectively, and were
synthesized by conventional oligonucleotide synthesis. The Sk-CRM4/Des was
cloned upstream of the MVM intron to drive the expression of the MD1 gene or
FST gene in the context of a single-stranded adeno-associated viral vector (ssAAV)
backbone that also contained a 49 bp synthetic polyadenylation site65. The con-
structs were designated as pssAAV-Sk-CRM4-Des-MD1 (Fig. 1h) and pssAAV-Sk-
CRM4-Des-FST (Fig. 1k), respectively. In this vector, the FST cDNA was linked to
a Luc reporter gene via a 2A polypeptide-encoding fragment. Cloning details are
available upon request.
AAV vector production and purification. AAV vectors were prepared as
described in the Supplementary Methods36. Genome-containing vectors and empty
AAV capsid particles were purified by cesium chloride gradient. The vector titer (in
vector genomes or vg/ml) for all vectors was determined by quantitative (q)PCR
(Supplementary Methods). Typically, vector titers achieved for all vectors were in














































































































































Fig. 8 Comparison of Sk-CRM4/Des chimeric promoter with conventional promoters in mdx mice model. The ssAAV9 vectors encodingMD1 and FST gene
under Sk-CRM4/Des chimeric promoter, Des, or CMV were co-injected as a combination therapy into mdx mice at a dose of 1 × 1011 vg/mouse or 5 × 1011
vg/mouse. a Treadmill test of the 20-week-old mdx mice (16 weeks post-injection) treated with the different constructs of therapeutic vectors compared
to the untreated mdx and wild-type C57BL/10ScSnJ mice. The results were shown as the distance covered. The percentages indicate the distance related
to untreated mdx mice. Statistical analysis using t-test *p < 0.05 (n= 4–5). b Human MD1 and FST mRNA quantification in skeletal muscles, i.e.,
gastrocnemius and quadriceps of treated mdx mice, expressed relative to the housekeeping gene Gapdh by qRT-PCR. c Quantification of human FST
protein as measured using ELISA. Results were presented as mean ± standard error of the mean. Statistical analysis using t-test *p < 0.05, **p < 0.01
(related to 1 × 1011 injected group of the same construct), #p < 0.05; mean+ s.e.m. (n= 4–5)
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Mice. This study was carried out in CB17/IcrTac/Prkdcscid mice (Taconic, Den-
mark), C57BL/6 mice (Janvier Labs, France) or SCID/mdx mice (kindly provided
by Dr. Y. Torrente and Mrs. M. Meregalli, University of Milan, Italy). The dys-
trophic mdx and CB57BL/10ScSnj mice models were purchased from Jackson
Laboratory, USA. All animal procedures were carried out at the Vrije Universiteit
Brussel and the University of Leuven (Belgium) and were approved by the
respective Institutional Animal Ethics Committees (i.e., KU Leuven & VUB
Ethische Commissie Dieren—ECD). Mice were housed under specific pathogen-
free (SPF)-like conditions; food and water were provided ad libitum. For each
cohorts of various experiments, mice were randomly selected from a group of mice
of same age and similar weight to standardize control and experimental groups as
much as possible. Mice and samples were coded based on the ear tag number. The
ear tag number was decoded after conducting the experiment. The designated
investigator injecting the vectors was blinded to the experimental outcome. The
investigators were blinded to the precise nature of the CRMs or vectors.
In vivo bioluminescence analysis. For the in vivo screening of the AAV vectors
containing the different Sk-CRMs and the Luc reporter gene, 2-days old CB17/
IcrTac/Prkdcscid mice were intravenously injected into the retro-orbital vein with
50 μl of purified AAV9 vectors (5 × 109 vg/mouse). The experimental mice were
subjected to bioluminescence imaging analysis at 5 and 6 weeks post-injection
using an in vivo optical imaging system (PhotonImager, Biospace Lab, Paris,
France). Alternatively, AAV9 vectors were injected intravenously into the tail vein
into adult 6-weeks-old CB17/IcrTac/Prkdcscid adult mice at a dose of 1 × 1010 vg
per mouse and analyzed by bioluminescence imaging 2 and 4 weeks post-injection.
Before imaging, mice were intravenously administered with a D-luciferin substrate
(30 mg/ml) at a dose of 150 mg/kg of body weight. Quantitative image analysis of
individual organs was performed at 7 weeks post vector injection for the mice that
were injected as neonates and at 6 weeks post vector injection for the injected adult
cohorts. In this case, mice were euthanized by cervical dislocation within 1-minute
post D-luciferin administration. In vivo bioluminescence was expressed in photons
(ph) s-1 cm-2 steradian (sr)-1 and displayed as a pseudo-color overlay onto a gray
scale animal image using a rainbow color scale. All images were scaled to the same
maximum and minimum, as represented in the color bar.
Transduction efficiency, biodistribution, and mRNA levels. Transduction effi-
ciency and biodistribution was evaluated by quantifying Luc transgene copy
numbers in the different organs and tissues, as described in Supplementary
Methods. The qPCR results were expressed as mean AAV copy number/100 ng of
genomic DNA. To quantify Luc mRNA levels in different tissues real-time qPCR
analysis was performed using Luc-specific primers (amplicon 206 bp) (Supple-
mentary Methods). All results were normalized to mRNA levels of the endogenous
murine glyceraldehyde-3-phosphate dehydrogenase (Gapdh) gene (amplicon 82
bp).
Chromatin immunoprecipitation assay (ChIP assay). To verify the biding of
selected TF on the cognate TFBS, ChIP assays were performed (Supplementary
Methods) 67. Genomic DNA regions of interest were isolated using 4 μg of SRF-
specific antibody (sc-335; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or a
CEBP-specific antibody (sc-150; Santa Cruz Biotechnology, Santa Cruz, CA, USA).
qPCR reactions were carried out in triplicate on specific genomic regions using
SYBR Green Supermix (Bio-Rad, USA). The resulting signals were normalized for
primer efficiency by carrying out qPCR for each primer pair using the genomic
input DNA with Sk-CRM4-specific forward and reverse primers. Negative control
primers were purchased from Active Motif (Carlsbad, CA, USA) (#71012) and are
specific for non-transcribed gene sequences on chromosome 17.
Analysis of therapeutic efficacy in vivo. Four-weeks-old SCID/mdx or mdx mice
were injected intravenously into the tail vein with the indicated doses of the
ssAAV9-Sk-CRM4-Des-MD1 (or ssAAV9-Sk-CRM4-Des-DM1Δ) and/or
ssAAV9-Sk-CRM4-Des-FST therapeutic vector. Control mice were injected with
phosphate buffered saline (PBS). Sixteen weeks post-injection, the treated and
control SCID/mdx or mdx mice and wild-type age-matched C57BL/6 or C57BL/
10ScSnJ mice were subjected to a treadmill test (Exer-3/6 open treadmill,
Columbus Instruments, USA) to determine correction of the dystrophic pheno-
type. The inclination of the belt was adjusted to 10° uphill before performing the
test. The initial speed was set at 10 mmin-1 and thereafter the speed was increased
by 1 mmin-1 every minute. The test was terminated at a point when the mice sat
for ≥ 5 s on the pulse grill. At that point the distance covered by the mice was
recorded and the total distance covered by the mice during the course of the test
was calculated by using the formula, according to the manufacturer’s instructions:
distance (in m)= (N+ n)/2)*(N− n+ 1) where N is the speed (in m min-1) at the
point of termination of the test and n is the speed (in m min-1) at the start point of
the test.
In vitro analysis of muscle contractile properties. Mice injected with the
ssAAV9-Sk-CRM4-Des-MD1Δ and ssAAV9-Sk-CRM4-Des-FST vectors (2 × 1010
vg per mouse) were euthanized 18 weeks post vector administration and the
extensor digitorum longus muscle was isolated from each mouse to perform the
force test. Age-matched C57BL/6 mice and untreated SCID/mdx mice were used as
controls. Functional analysis was performed using an Aurora 1200 A in vitro
muscle test system, as previously reported67. Briefly, freshly isolated muscles were
electrically stimulated in a temperature-controlled (30° C) chamber, filled with
Krebs-Ringer bicarbonate buffer solution containing 10 mM glucose and con-
tinuously gassed with 99% O2. The electrical stimulation was performed by means
of a couple of platinum electrodes, located 4 mm from each side of the muscle.
Tetanic force was evoked by stimulation with a train of 0.2 ms pulses (150 Hz
pulses for 0.5 s).
Histological analysis. Mice injected with the ssAAV9-Sk-CRM4-Des-MD1Δ and
ssAAV9-Sk-CRM4-Des-FST vectors (2 × 1010 vg per mouse) were euthanized
18 weeks post vector injection and the tibialis anterior muscles were harvested for
hematoxylin and eosin staining and (Supplementary Methods). For immuno-
fluorescence staining, the heart and the tibialis anterior muscles were subjected to
cryofixation and stained for mouse laminin and human dystrophin using specific
antibodies and the appropriate fluorescein-isothyocyanate (FITC) or
tetramethylrhodamineisothiocyanate-conjugated (TRITC) anti-mouse or anti-
rabbit (1:500, Life Technologies, Carlsbad, CA, USA) (Supplementary Methods).
Nuclear staining was performed using 4’,6-diamidino-2-phenylindole (DAPI;
Hoechst nucleic acid stain, Life technologies, USA) (1:1000 dilution) for 1 h at
room temperature. For assessment of the immune response, infiltration of CD4+
and CD8+ T-cells was analyzed. CD4 and CD8-specific antibodies (1:500; Cell
signaling, USA) were used as primary antibody to detect mouse T cells. After
washing, the samples were subjected to HRP-conjugated secondary antibody
(1:2000; Abcam, UK). Substrate was added (3,3’-diaminobenzidine tetra-
hydrochloride) (DAB kit, Cell signaling, USA) and tissue sections were counter-
stained using hematoxylin. Spleen sections were used as control. Cellular apoptosis
was assessed in situ based on a TUNEL assay. Modified dUTPs were, therefore,
incorporated by the enzyme terminal deoxynucleotidyl transferase (TdT) at the 3’-
OH ends of fragmented DNA using Click-iT® TUNEL Alexa Fluor647® Imaging
Assay (Life Technologies, Carlsbad, CA, USA), according to the manufacturing
protocol. Tissue samples were then analyzed under a fluorescent microscope
(Nikon Eclipse 80i) and images were processed by NIS Elements 4.30.02 software.
FST enzyme-linked immunosorbent assay. Human FST was quantified from the
muscles of SCID/mdx mice by an enzyme-linked immunosorbent assay (ELISA)
with a human FST-specific immunoassay kit (Quantikine; R&D Systems, Min-
neapolis, USA), according to the manufacturer’s protocol. Briefly, total soluble
protein was extracted from 50 mg gastrocnemius, quadriceps, and/or tibialis
anterior muscle with CelLytic MT Mammalian Tissue Lysis reagent (Sigma, St.
Louis, Missouri, USA). A total of 100 μl of lysate was loaded per well, and muscle
FST concentrations were determined against a standard curve made with recom-
binant human FST provided by the manufacturer.
Western blotting. Proteins were extracted from skeletal muscles, diaphragm, or
heart by solubilization in lysis buffer (50 mM Tris, 5 mM EDTA, 5% sodium
dodecyl sulfate, 5% glycerol) supplied with 1x protease inhibitor cocktails (Thermo
Fisher Scientific, USA). The total protein concentrations were determined using RC
DC™ Protein Assay (Bio-Rad, USA), per manufacturer’s protocol. Then 50–100
microgram of proteins were mixed with sample buffer (Bio-Rad, USA) and loaded
into 4–15% TGX gels (Bio-rad, USA) for sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. The proteins were transferred to 0.45 μm polyvinylidene
fluoride membranes (Invitrogen, USA) using Towbin buffer (Bio-rad, USA).
Membranes were blocked with 3% blotting-grade blocker (Bio-rad, USA) for 1 h at
room temperature following by incubation with 1:100 mouse anti-human dystro-
phin antibody (NCL-DYS3; Novocatsra, UK) or 1:1000 rabbit anti-GAPDH anti-
body (#2118; Cell Signaling Technology, Netherland) in 3% Blotting-grade blocker.
After washing three times with 1x TBS-T buffer, the secondary antibodies com-
patible with primary antibody, e.g., horseradish peroxidase (HRP)–conjugated
1:2000 goat anti-mouse (#7076; Cell Signaling Technology, Netherland) and
1:10,000 goat anti-rabbit IgG (#7074; Cell Signaling Technology, Netherland) were
incubated with the membranes for 1 h at room temperature. Afterward, mem-
branes were washed three times for 5 min each with TBS-T buffer. The chemilu-
minescent signal was developed using the SuperSignal West Pico PLUS substrate
(Thermo Fisher Scientific, USA). The sizes of protein were estimated using
MagicMarker XP Protein Standard (LC5602; Invitrogen, USA) (Supplementary
Fig. 6). The signals were quantified under Image-J software.
Statistics. Data were analyzed using Microsoft Excel Statistics package or Prism
Graphpad. Values shown in the figures are the mean+ s.e.m. Specific values were
obtained by comparison using t-test or one-way ANOVA. Samples were tested (n
= 3–5, twice) and representative results are shown.
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
The authors declare that all data supporting the findings of this investigation are
available within the article, its Supplementary Information, and from the corre-
sponding authors, upon reasonable request. All comprehensive western blot images
including the molecular weight markers were presented in Supplementary Fig. 6.
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